A Prospective, Randomized, Blinded Study of MultiHance on 1.5T and 3.0T Strength Field: An Evaluation of Brain, Optic Nerve and Spinal Cord Protocols in Multiple Sclerosis Patients

Robert Zivadinov¹, Sara Hussein¹, Cheryl Kennedy¹, Niels Bergsland¹, Christina Brooks, Michael G. Dwyer¹

This was prospective, randomized, cross-over, blinded study that included 86 RRMS patients who underwent brain, 53 spinal cord and 40 optic nerve MRI exams at both 1.5T and 3.0T. The same scanning protocol was applied at two scanner field strengths (1.5T and 3.0T) after administration of MultiHance 0.1 mmol/kg body weight (injection, 529 mg/mL) with 5 min delay between injection and scanning. The use of a high relaxivity contrast agent, such as MultiHance at 3.0T field strength increases the diagnostic benefit in detecting enhancing lesions when compared intra-individually to the application of the same agent at 1.5 T.